Aura Biosciences, Inc.
About Aura Biosciences, Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$106.2M
- Total assets
- $169.4M
- Market cap
- $685.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$112.8M
- Income tax
- $108.0K
- Net income
- -$106.2M
- EPS (basic)
- $-1.76
- EPS (diluted)
- $-1.76
Balance sheet
- Total assets
- $169.4M
- Current assets
- $149.7M
- Total liabilities
- $32.5M
- Current liabilities
- $18.4M
- Shareholders’ equity
- $136.9M
Cash flow
- Operating cash flow
- -$84.7M
- Investing cash flow
- $35.6M
- Financing cash flow
- $77.2M
- Net cash flow
- $28.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $685.5M
- EPS (diluted)
- $-1.76
- Shares outstanding
- 105.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 29, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $106.2M.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aura Biosciences, Inc..
Write a review
News about Aura Biosciences, Inc.
News & sentiment via Polygon.io
